Technical Data
M2800-04
MDM2 (Murine Double Minute-2)
Description:
MDM2 acts as a major regulator of the tumor suppressor p53 by targeting its destruction. Since the MDM2 gene is frequently amplified in some types of cancers and shows oncogenic activity, it is considered to be an oncogene. Overexpression of MDM2 has been observed in some carcinomas, sarcomas, and leukemias. In breast cancer, MDM2 expression is associated with the tumor grade, and higher MDM2 levels directly correlate with the onset of lymph node metastases and shortened patients survival. In glioblastoma, MDM2 oncogene activation appears to occur late in tumor progression and may be characteristic as a negative prognostic marker.

Applications:
Suitable for use in Immunohistochemistry. Other applications not tested.

Recommended Dilutions:
Immunohistochemistry: Frozen, formalin-fixed paraffin embedded tissue sections. Requires epitope retrieval using EDTA, pH 8.
Optimal dilutions to be determined by the researcher.

Recommended Positive Control:
Glioma

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
MabIgG2b,k4H309Purified
SizeStorageShippingSourceHost
200ul-20CBlue IceHumanMouse
Concentration:
~0.15mg/ml
Immunogen:
Synthetic peptide corresponding to the N-terminal region of human MDM2 protein. Cellular Localization: Nucleus.
Purity:
Purified
Form
Supplied as a liquid in PBS, pH 7.4, 1% BSA, 0.1% sodium azide.
Specificity:
Recognizes human MDM2
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Gunther, T., et al., J. Cancer Res. Clin. Oncol. 123(7): 388-394 (1997). 2. Jiang, M., et al., Int. J. Cancer 74(5): 529-534 (1997). 3. Schiebe, M., et al., J. Neurooncol. 49(3): 197-203 (2000).